Clinical and pharmacoeconomic evaluation of antifungal prophylaxis with continuous micafungin in patients undergoing allogeneic stem cell transplantation: A six‐year cohort analysis-Reference-Cited by-同舟云学术

Clinical and pharmacoeconomic evaluation of antifungal prophylaxis with continuous micafungin in patients undergoing allogeneic stem cell transplantation: A six‐year cohort analysis

Published:2021-01-06 Issue:4 Volume:64 Page:
ISSN:0933-7407
Container-title:Mycoses
language:en
Short-container-title:Mycoses

Author:

Wingen‐Heimann Sebastian M.¹²^ORCID,Cornely Oliver A.¹³⁴⁵^ORCID,Vehreschild Maria J.G.T.¹³⁶^ORCID,Wisplinghoff Hilmar⁷⁸⁹,Franke Bernd¹,Schons Max¹,Bergwelt‐Baildon Michael¹,Scheid Christof¹,Vehreschild Jörg Janne¹³^ORCID

Affiliation:

1. Department I of Internal Medicine Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf University Hospital of Cologne Cologne Germany

2. FOM University of Applied Sciences Cologne Germany

3. German Center for Infection Research (DZIF), partner site Bonn‐Cologne Cologne Germany

4. Cologne Excellence Cluster on Cellular Stress Responses in Aging‐Associated Diseases (CECAD) University Hospital of Cologne Cologne Germany

5. Clinical Trials Centre Cologne (ZKS) University Hospital of Cologne Cologne Germany

6. Department of Internal Medicine Infectious Diseases University Hospital Frankfurt Goethe University Frankfurt Frankfurt am Main Germany

7. Institute for Medical Microbiology, Immunology and Hygiene University Hospital of Cologne Cologne Germany

8. Wisplinghoff Laboratories Cologne Germany

9. Institute for Virology and Microbiologa WittenHerdecke University Witten Germany

Publisher

Wiley

Subject

Infectious Diseases,Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/myc.13232

Reference27 articles.

1. Epidemiology and Outcome of Invasive Fungal Infection in Adult Hematopoietic Stem Cell Transplant Recipients: Analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance Registry

2. Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation

3. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients

4. Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospitals

5. Healthcare burden of probable and proven invasive mucormycosis: a multi-centre cost-of-illness analysis of patients treated in tertiary care hospitals between 2003 and 2016

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review of prophylactic regimens to prevent invasive fungal infections in hematology patients undergoing chemotherapy or stem cell transplantation;Expert Review of Hematology;2023-12-02

2. Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO);Journal of Antimicrobial Chemotherapy;2023-06-13